News

Article

FDA Approves Digital Pill

The agency approved Abilify MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication.

On Nov. 13, 2017, FDA announced it has approved Abilify MyCite (Otsuka Pharmaceutical Co., Ltd.), which is the first drug in the United States that has a digital ingestion tracking system. The pill has an embedded ingestible sensor that records when the medication is taken. Abilify MyCite treats schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and is also used as an add-on treatment for depression in adults.

The pill’s sensor sends a message to a wearable patch that transmits information to a mobile application, which allows patients, caregivers, and physicians to track the ingestion of the drug on a smartphone and through a web-based portal. The sensor and patch are made by Proteus Digital Health. Labeling information stresses that it has not been proven if tracking such information improves treatment regimens. Abilify MyCite also contains a boxed warning about the risks of antipsychotic drugs.

“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More